Literature DB >> 26804002

Mural nodule of 10 mm or larger as predictor of malignancy for intraductal papillary mucinous neoplasm of the pancreas: Pathological and radiological evaluations.

Natsuko Kawada1, Hiroyuki Uehara2, Shigenori Nagata3, Mutsumi Tsuchishima4, Mikihiro Tsutsumi4, Yasuhiko Tomita3.   

Abstract

BACKGROUND: We had previously reported that mural nodule (MN) ≥10 mm was optimal predictor of malignancy for intraductal papillary mucinous neoplasm (IPMN). However, little is known about its microscopic findings and imaging detectability.
METHODS: Medical records and resected specimens of consecutive patients with IPMNs harboring MN ≥ 10 mm were reviewed. Imaging detectability was determined on reports basis. Malignant IPMNs (noninvasive + invasive carcinomas) were microscopically classified according to localization of high-grade dysplasia (HGD) within MN.
RESULTS: Thirty-six patients were included. Imaging detectability of MN ≥ 10 mm in CT, MRI, US and EUS were 64%, 68%, 89%, and 97%, respectively. Thirty-three (92%) IPMNs were histologically diagnosed as malignant. Thirty percent of malignant IPMNs were classified into "diffuse HGD within MN", 40% into "focal HGD within MN", and 30% into "HGD outside MN", in which HGD was not located within MN but in low papillary epithelia around MN. Overall sensitivity of pancreatic juice cytology was calculated as 58%, and for "diffuse HGD within MN", "focal HGD within MN", and "HGD outside MN" as 80%, 62%, and 30%, respectively (p = 0.0237). Univariate-analysis showed localization of HGD within MN was associated with true positive cytology (OR = 5.33, p = 0.043).
CONCLUSIONS: Detectability of MN ≥ 10 mm is excellent in US and EUS. Although HGD is observed within MN in 70% of malignant IPMNs, HGD is located only in low papillary epithelia around MN in the remaining 30%, in which sensitivity of pancreatic juice cytology is shown to be inadequate.
Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EUS; Histological subtype; IPMN; Imaging detectability; Indication for resection; Mural nodule

Mesh:

Year:  2015        PMID: 26804002     DOI: 10.1016/j.pan.2015.12.008

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  8 in total

Review 1.  Cystic pancreatic lesions: From increased diagnosis rate to new dilemmas.

Authors:  S Nougaret; L Mannelli; M-A Pierredon; V Schembri; B Guiu
Journal:  Diagn Interv Imaging       Date:  2016-11-11       Impact factor: 4.026

Review 2.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

3.  European evidence-based guidelines on pancreatic cystic neoplasms.

Authors: 
Journal:  Gut       Date:  2018-03-24       Impact factor: 23.059

4.  MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) VERSUS ENDOSONOGRAPHY-GUIDED FINE NEEDLE ASPIRATION (EUS-FNA) FOR DIAGNOSIS AND FOLLOW-UP OF PANCREATIC INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS.

Authors:  Débora Azeredo Pacheco Dias Costa; João Guilherme Guerra; Suzan Menasce Goldman; Rafael Kemp; José Sebastião Santos; José Celso Ardengh; Carmen Australia Paredes Marcondes Ribas; Paulo Afonso Nunes Nassif; Jurandir Marcondes Ribas-Filho
Journal:  Arq Bras Cir Dig       Date:  2019-12-20

5.  Diagnostic Accuracy of Magnetic Resonance Cholangiopancreatography to Detect Benign and Malignant Biliary Strictures.

Authors:  Niloufar Shabanikia; Atoosa Adibi; Shadi Ebrahimian
Journal:  Adv Biomed Res       Date:  2021-11-26

6.  Evaluating the malignant potential of intraductal papillary mucinous neoplasms of the pancreas: added value of non-enhanced endoscopic ultrasound to supplement non-enhanced magnetic resonance imaging.

Authors:  Takao Igarashi; Hirokazu Ashida; Kazuhiko Morikawa; Keitaro Enoki; Kazuyoshi Ohki; Gou Kawakami; Hiroya Ojiri
Journal:  Pol J Radiol       Date:  2018-09-12

7.  Predictive Features of Malignancy in Branch Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Meta-Analysis.

Authors:  Wooil Kwon; Youngmin Han; Yoonhyeong Byun; Jae Seung Kang; Yoo Jin Choi; Hongbeom Kim; Jin-Young Jang
Journal:  Cancers (Basel)       Date:  2020-09-14       Impact factor: 6.639

8.  The efficacy of pancreatic juice cytology with liquid-based cytology for evaluating malignancy in patients with intraductal papillary mucinous neoplasm.

Authors:  Kazuya Miyamoto; Kazuyuki Matsumoto; Hironari Kato; Ryuichi Yoshida; Yuzo Umeda; Hirohumi Inoue; Takehiro Tanaka; Akihiro Matsumi; Yosuke Saragai; Yuki Fujii; Tatsuhiro Yamazaki; Daisuke Uchida; Takeshi Tomoda; Shigeru Horiguchi; Takahito Yagi; Hiroyuki Okada
Journal:  BMC Gastroenterol       Date:  2020-09-29       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.